 Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.220
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 6 | 6 | | 1981 | 0 | 6 | 6 | | 1982 | 0 | 8 | 8 | | 1983 | 0 | 6 | 6 | | 1984 | 0 | 4 | 4 | | 1985 | 0 | 8 | 8 | | 1986 | 0 | 7 | 7 | | 1987 | 0 | 12 | 12 | | 1988 | 0 | 10 | 10 | | 1989 | 0 | 18 | 18 | | 1990 | 0 | 24 | 24 | | 1991 | 0 | 25 | 25 | | 1992 | 0 | 28 | 28 | | 1993 | 0 | 39 | 39 | | 1994 | 0 | 30 | 30 | | 1995 | 0 | 30 | 30 | | 1996 | 0 | 22 | 22 | | 1997 | 0 | 33 | 33 | | 1998 | 0 | 32 | 32 | | 1999 | 0 | 35 | 35 | | 2000 | 0 | 48 | 48 | | 2001 | 0 | 58 | 58 | | 2002 | 0 | 75 | 75 | | 2003 | 1 | 71 | 72 | | 2004 | 0 | 79 | 79 | | 2005 | 0 | 70 | 70 | | 2006 | 0 | 66 | 66 | | 2007 | 1 | 67 | 68 | | 2008 | 1 | 66 | 67 | | 2009 | 1 | 56 | 57 | | 2010 | 0 | 62 | 62 | | 2011 | 0 | 57 | 57 | | 2012 | 0 | 60 | 60 | | 2013 | 0 | 41 | 41 | | 2014 | 0 | 53 | 53 | | 2015 | 3 | 45 | 48 | | 2016 | 0 | 40 | 40 | | 2017 | 0 | 31 | 31 | | 2018 | 0 | 41 | 41 | | 2019 | 0 | 33 | 33 | | 2020 | 0 | 8 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
-
Strohbehn GW, Reid PD, Ratain MJ. Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19. Clin Pharmacol Ther. 2020 09; 108(3):425-427.
-
Elzein C, Urbas C, Hughes B, Li Y, Lefaiver C, Ilbawi M, Vricella L. Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass. World J Pediatr Congenit Heart Surg. 2020 07; 11(4):417-423.
-
Huebinger RM, Zaidi HQ, Tataris KL, Weber JM, Pearlman KS, Markul E, Stein-Spencer L, Richards CT. Retrospective Study of Midazolam Protocol for Prehospital Behavioral Emergencies. West J Emerg Med. 2020 Apr 21; 21(3):677-683.
-
Mann D, Antinew J, Knapp L, Almas M, Liu J, Scavone J, Yang R, Modequillo M, Makedonska I, Ortiz M, Kyrychenko A, Nordli D, Farkas V, Farkas MK. Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: A double-blind, placebo-controlled, video-electroencephalographic trial. Epilepsia. 2020 04; 61(4):617-626.
-
Patel NH, Xu J, Saleh T, Wu Y, Lima S, Gewirtz DA. Influence of nonprotective autophagy and the autophagic switch on sensitivity to cisplatin in non-small cell lung cancer cells. Biochem Pharmacol. 2020 05; 175:113896.
-
Nazari F, Oklejas AE, Nör JE, Pearson AT, Jackson TL. In Silico Models Accurately Predict In Vivo Response for IL6 Blockade in Head and Neck Cancer. Cancer Res. 2020 04 01; 80(7):1451-1460.
-
Su Y, Han Y, Liu J, Qiu Y, Tan Q, Zhou Z, Yu YZ, Chen J, Giger ML, Lure FYM, Luo Z. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: three case reports. J Xray Sci Technol. 2020; 28(5):885-892.
-
Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246.
-
Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|